SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017
Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.BMC cancer · 2018Pooled it
- The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.BMC complementary and alternative medicine · 2018Pooled it
- Ghrelin for the management of cachexia associated with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Practical prescribing in cancer cachexia.Current opinion in supportive and palliative care · 2026Review
- Ovarian cancer and malnutrition: a literature review.Translational cancer research · 2025Review
- Sarcopenic obesity: a review.Archives of endocrinology and metabolism · 2025Review
- Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study.Frontiers in oncology · 2025Article
- Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine.Sports medicine and health science · 2024Review
- The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.Cancer management and research · 2023Review
- Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.Trends in endocrinology and metabolism: TEM · 2021Review
- Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery.International journal of molecular sciences · 2020Review
- Article
- Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis.BMC complementary and alternative medicine · 2019Article
- Effect of progressive sarcopenia during postoperative 6 months on long-term prognosis of completely resected lung cancer.Journal of thoracic disease · 2019Article
- Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer.JNCI cancer spectrum · 2019Article
- Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review.Therapeutics and clinical risk management · 2019Review
- Inter-tissue communication in cancer cachexia.Nature reviews. Endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the therapeutic effects of Anamorelin on patients with cancer anorexia-cachexia syndrome (CACS) based on a meta-analysis of published randomized trials.
methodsWe searched PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases. Data from each selected study were evaluated individually. All continuous outcomes were calculated by the mean difference or standardized mean difference with 95% confidence interval for each study. Heterogeneity was assessed by using the Chi
resultAt last, four studies were included from 284 records. In three studies, lean body mass was reported and there was a significant difference between placebo and Anamorelin groups (P < 0.00001), without significant heterogeneity (I
conclusionIn the included studies, Anamorelin had some positive effects to relieve the symptoms and improved the quality of life. However, the heterogeneity was apparent, so the clinical effects of Anamorelin should be further validated by increasing the sample size, varying the range of doses during treatment, and observing other outcomes. We are still confident for the future application of Anamorelin in phase III clinical trials.
Indexed as
Identifiers
28074289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.